These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 8545745)

  • 1. A phase I trial of hypoxoside as an oral prodrug for cancer therapy--absence of toxicity.
    Smit BJ; Albrecht CF; Liebenberg RW; Kruger PB; Freestone M; Gouws L; Theron E; Bouic PJ; Etsebeth S; van Jaarsveld PP
    S Afr Med J; 1995 Sep; 85(9):865-70. PubMed ID: 8545745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetic behaviour of hypoxoside taken orally by patients with lung cancer in a phase I trial.
    Albrecht CF; Kruger PB; Smit BJ; Freestone M; Gouws L; Miller R; van Jaarsveld PP
    S Afr Med J; 1995 Sep; 85(9):861-5. PubMed ID: 8545744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphological characterisation of the cell-growth inhibitory activity of rooperol and pharmacokinetic aspects of hypoxoside as an oral prodrug for cancer therapy.
    Albrecht CF; Theron EJ; Kruger PB
    S Afr Med J; 1995 Sep; 85(9):853-60. PubMed ID: 8545743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic behaviour and cardiovascular effects of intravenously administered hypoxoside and rooperol.
    Coetzee JF; Kruger PB; Albrecht CF; Jahed N; van Jaarsveld PP
    Arzneimittelforschung; 1996 Oct; 46(10):997-1000. PubMed ID: 8931895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer.
    Besse B; Planchard D; Veillard AS; Taillade L; Khayat D; Ducourtieux M; Pignon JP; Lumbroso J; Lafontaine C; Mathiot C; Soria JC
    Lung Cancer; 2012 Apr; 76(1):78-83. PubMed ID: 22186627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on hypoxoside and rooperol analogues from Hypoxis rooperi and Hypoxis latifolia and their biotransformation in man by using high-performance liquid chromatography with in-line sorption enrichment and diode-array detection.
    Kruger PB; Albrecht CF; Liebenberg RW; van Jaarsveld PP
    J Chromatogr B Biomed Appl; 1994 Dec; 662(1):71-8. PubMed ID: 7894695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.
    Spigel DR; Hainsworth JD; Burkett ER; Burris HA; Yardley DA; Thomas M; Jones SF; Dickson NR; Scullin DC; Bradof JE; Rubinsak JR; Brierre JE; Greco FA
    Clin Lung Cancer; 2005 Sep; 7(2):127-32. PubMed ID: 16179100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer.
    Tibaldi C; Bernardini I; Chella A; Russo F; Vasile E; Malventi M; Falcone A
    Clin Lung Cancer; 2006 May; 7(6):401-5. PubMed ID: 16800966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
    Ross HJ; Blumenschein GR; Aisner J; Damjanov N; Dowlati A; Garst J; Rigas JR; Smylie M; Hassani H; Allen KE; Leopold L; Zaks TZ; Shepherd FA
    Clin Cancer Res; 2010 Mar; 16(6):1938-49. PubMed ID: 20215545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin and etoposide before definitive radiation therapy for inoperable squamous carcinoma, adenocarcinoma, and large cell carcinoma of the lung: a phase I-II study of the Radiation Therapy Oncology Group.
    Cox JD; Samson MK; Herskovic AM; Abrams R; Koehler M
    Cancer Treat Rep; 1986 Oct; 70(10):1219-20. PubMed ID: 3019546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
    Mu XL; Li LY; Zhang XT; Wang SL; Wang MZ
    BMC Cancer; 2004 Aug; 4():51. PubMed ID: 15318946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer.
    Souquet PJ; Fournel P; Bohas CH; Fortune IC; Chatte G
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):8-10. PubMed ID: 8610239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of oral topotecan in advanced non-small cell lung cancer.
    White SC; Cheeseman S; Thatcher N; Anderson H; Carrington B; Hearn S; Ross G; Ranson M
    Clin Cancer Res; 2000 Mar; 6(3):868-73. PubMed ID: 10741709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
    Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Burris HA; Morrissey LH; Thomas M; Erland JB; Butts JA; Joseph G; Kalman L; Greco FA
    Cancer J; 2000; 6(3):151-6. PubMed ID: 10882330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.
    Muggia FM; Wu X; Spicer D; Groshen S; Jeffers S; Leichman CG; Leichman L; Chan KK
    Clin Cancer Res; 1996 Sep; 2(9):1461-7. PubMed ID: 9816321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A phase II study of oral VP-16 in primary lung cancer].
    Matsui Y; Ohshima S; Kado M; Nakayama M; Shimokata K; Sakai S; Ito F; Chikata E; Hara K; Kanda T
    Gan To Kagaku Ryoho; 1985 Sep; 12(9):1801-7. PubMed ID: 2994576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hybrid (intravenous and oral) administration of vinorelbine plus cisplatinum followed by oral vinorelbine as first-line therapy of advanced non-small cell lung cancer: a phase II study.
    Martoni AA; Melotti B; Sperandi F; Giaquinta S; Piana E; Pavesi L; Da Prada G; Lelli G
    Lung Cancer; 2008 Jun; 60(3):387-92. PubMed ID: 18160123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of DA-125, a novel anthracycline, in advanced non-small-cell lung cancer.
    Kang YK; Ryoo BY; Kim TY; Im YH; Kim BS; Park YH; Lee CT
    Cancer Chemother Pharmacol; 1999; 44(6):518-21. PubMed ID: 10550574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A phase II study of UFT in non-small cell lung cancer].
    Shimizu E; Kimura K; Sone S; Inoue I; Nakamura Y; Noda Y; Hojo F; Yagi M; Nakanishi S; Yamasaki K
    Gan To Kagaku Ryoho; 1986 Oct; 13(10):2970-3. PubMed ID: 3021068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.